InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

Current share price for CHM : $0.013 0.002 (13.33%)+

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$1 $5 million Placement to progress CHM CDH17 trial 21 Oct 2024 11:48AM $0.014 $0.013 fallen by 7.14%
$1 Change in substantial holding - PH 16 Oct 2024 6:36PM $0.014 $0.013 fallen by 7.14%
$1 Notice of Annual General Meeting 14 Oct 2024 5:15PM $0.014 $0.013 fallen by 7.14%
$1 2024 Annual Report update 11 Oct 2024 4:17PM $0.014 $0.013 fallen by 7.14%
$1 AML patient achieves Complete Response in CHM CORE-NK trial 7 Oct 2024 9:45AM $0.014 $0.013 fallen by 7.14%
$1 2024 Annual Report update 4 Oct 2024 12:05PM $0.014 $0.013 fallen by 7.14%
$1 Suspension from Quotation 1 Oct 2024 9:33AM $0.014 $0.013 fallen by 7.14%
$1 Achieve Clinics collaboration to expand reach of CHM CDH17 25 Sep 2024 8:25AM $0.013 $0.013 fallen by 0%
$1 Notice under section 708A 20 Sep 2024 4:35PM $0.014 $0.013 fallen by 7.14%
$1 Application for quotation of securities - CHM 20 Sep 2024 4:33PM $0.014 $0.013 fallen by 7.14%
$1 University of Pennsylvania joins CHM CDH17 Phase 1/2 trial 11 Sep 2024 9:38AM $0.015 $0.013 fallen by 13.33%
$1 Notice under section 708A 30 Aug 2024 5:27PM $0.017 $0.013 fallen by 23.53%
$1 Notification regarding unquoted securities - CHM 30 Aug 2024 5:24PM $0.017 $0.013 fallen by 23.53%
$1 Application for quotation of securities - CHM 30 Aug 2024 5:22PM $0.017 $0.013 fallen by 23.53%
$1 Appendix 4E and Preliminary Final Report 30 Aug 2024 10:04AM $0.019 $0.013 fallen by 31.58%
$1 First patient dosed in Phase 1/2 trial of CHM CDH17 28 Aug 2024 9:57AM $0.016 $0.013 fallen by 18.75%
$1 Phase 1/2 CHM CDH17 CAR-T GMP Manufacturing Complete 16 Aug 2024 9:21AM $0.017 $0.013 fallen by 23.53%
$1 Chimeric receives $1.5 M advance on FY24 R&D tax incentive 13 Aug 2024 10:05AM $0.019 $0.013 fallen by 31.58%
$1 Chimeric partnering with Cell Therapies Australia 9 Aug 2024 9:06AM $0.016 $0.013 fallen by 18.75%
$1 Notice under section 708A 2 Aug 2024 4:29PM $0.017 $0.013 fallen by 23.53%
$1 Application for quotation of securities - CHM 2 Aug 2024 4:23PM $0.017 $0.013 fallen by 23.53%
$1 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2024 9:37AM $0.020 $0.013 fallen by 35%
$1 Investor Presentation 25 Jul 2024 11:55AM $0.021 $0.013 fallen by 38.10%
$1 First patient enrolled in CHM CDH17 Phase 1/2 clinical trial 22 Jul 2024 10:12AM $0.019 $0.013 fallen by 31.58%
$1 Notice under section 708A 28 Jun 2024 4:38PM $0.020 $0.013 fallen by 35%

201 - 225 of 643 results

Page 9 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.